{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:29:05Z","timestamp":1786994945112,"version":"build-2736575974"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.neuropharm.2025.110658","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T15:07:23Z","timestamp":1756134443000},"page":"110658","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["IDOR-1104-0086, a novel Kv7 channel activator with antiseizure effects in rodents"],"prefix":"10.1016","volume":"280","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3577-7869","authenticated-orcid":false,"given":"Melanie","family":"Kessler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3914-1535","authenticated-orcid":false,"given":"Andreas","family":"M\u00fchlemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9476-5466","authenticated-orcid":false,"given":"Malgorzata Anna","family":"Mis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7590-7786","authenticated-orcid":false,"given":"Romain","family":"Siegrist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0863-2865","authenticated-orcid":false,"given":"Swen","family":"Seeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5497-776X","authenticated-orcid":false,"given":"Caroline","family":"Deymier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cary-Ann","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Roellinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6701-574X","authenticated-orcid":false,"given":"Tsvetomira","family":"Atanasova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0260-2756","authenticated-orcid":false,"given":"Catherine","family":"Roch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9923-6555","authenticated-orcid":false,"given":"Michel Alexander","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.neuropharm.2025.110658_bib1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0920-1211(01)00302-3","article-title":"Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy","volume":"47","author":"Barton","year":"2001","journal-title":"Epilepsy Res."},{"issue":"10","key":"10.1016\/j.neuropharm.2025.110658_bib2","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1111\/epi.18075","article-title":"Progress report on new medications for seizures and epilepsy: a summary of the 17th eilat conference on new antiepileptic drugs and devices (EILAT XVII). II. Drugs in more advanced clinical development","volume":"65","author":"Bialer","year":"2024","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110658_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2008.09.005","article-title":"Progress report on new antiepileptic drugs: a summary of the ninth eilat conference (EILAT IX)","volume":"83","author":"Bialer","year":"2009","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2025.110658_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2019.106580","article-title":"Safety of retigabine in adults with partial-onset seizures after long-term exposure: focus on unexpected ophthalmological and dermatological events","volume":"102","author":"Brickel","year":"2020","journal-title":"Epilepsy Behav."},{"issue":"20","key":"10.1016\/j.neuropharm.2025.110658_bib5","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1212\/WNL.0b013e3181fd6170","article-title":"Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy","volume":"75","author":"Brodie","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2025.110658_bib6","series-title":"Recommended Voltage Protocols to Study drug-cardiac Ion Channel Interactions Using Recombinant Cell Lines","year":"2021"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110658_bib7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4172\/Neuropsychiatry.1000175","article-title":"Current insight into the role of voltage-gated potassiumion channel 7 (Kv7) channels: an emerging therapy target against epilepsy","volume":"7","author":"Diao","year":"2017","journal-title":"Neuropsychiatry"},{"issue":"18","key":"10.1016\/j.neuropharm.2025.110658_bib8","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1212\/WNL.0b013e3182194bd3","article-title":"Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy","volume":"76","author":"French","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2025.110658_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/epi4.70015","article-title":"Interim analysis of the long-term efficacy and safety of azetukalner in an ongoing open-label extension study following a phase 2b clinical trial (X-TOLE) in adults with focal epilepsy","author":"French","year":"2025","journal-title":"Epilepsia Open"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110658_bib10","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1021\/acs.chemrestox.8b00313","article-title":"An investigation into retigabine (Ezogabine) associated dyspigmentation in rat eyes by MALDI imaging mass spectrometry","volume":"32","author":"Groseclose","year":"2019","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.neuropharm.2025.110658_bib11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejphar.2014.01.017","article-title":"Kv7 channels as targets for anti-epileptic and psychiatric drug-development","volume":"726","author":"Grunnet","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110658_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173440","article-title":"In vitro and in vivo characterization of Lu AA41178: a novel, brain penetrant, pan-selective Kv7 potassium channel opener with efficacy in preclinical models of epileptic seizures and psychiatric disorders","volume":"887","author":"Grupe","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110658_bib13","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.2147\/NDT.S256699","article-title":"Clinical management of drug resistant epilepsy: a review on current strategies","volume":"17","author":"Guery","year":"2021","journal-title":"Neuropsychiatric Dis. Treat."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110658_bib14","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1528-1167.2011.03365.x","article-title":"The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy","volume":"53","author":"Gunthorpe","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2025.110658_bib15","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211037430","article-title":"Efficacy and tolerability of antiseizure drugs","volume":"14","author":"Hakami","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110658_bib16","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1111\/1440-1681.13537","article-title":"Age dependent effects of retigabine on absence seizure in WAG\/rij rats; an experimental study","volume":"48","author":"Karadenizli","year":"2021","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110658_bib17","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1111\/epi.12200","article-title":"Clinical spectrum of early onset epileptic encephalopathies caused by KCNQ2 mutation","volume":"54","author":"Kato","year":"2013","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110658_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2307\/3570549","article-title":"Chemical protection against ionizing radiation. I. Sampling methods for screening compounds in radiation protection studies with mice","volume":"7","author":"Kimball","year":"1957","journal-title":"Radiat. Res."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110658_bib19","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1528-1167.2011.03364.x","article-title":"The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: implications for clinical use","volume":"53","author":"Large","year":"2012","journal-title":"Epilepsia"},{"issue":"5\u20136","key":"10.1016\/j.neuropharm.2025.110658_bib20","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/17512433.2024.2337012","article-title":"A profile of azetukalner for the treatment of epilepsy: from pharmacology to potential for therapy","volume":"17","author":"Lattanzi","year":"2024","journal-title":"Expet Rev. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110658_bib22","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1124\/jpet.106.104968","article-title":"The mechanism of carbamazepine aggravation of absence seizures","volume":"319","author":"Liu","year":"2006","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2025.110658_bib21","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1111\/bph.14026","article-title":"Selective targeting of M-type potassium Kv7.4 channels demonstrates their role in the regulation of dopaminergic neuronal excitability and depression-like behavior","volume":"174","author":"Li","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110658_bib23","doi-asserted-by":"crossref","DOI":"10.1007\/164_2021_458","article-title":"Pharmacological activation of neuronal voltage-gated Kv7\/KCNQ\/M-channels for potential therapy of epilepsy and pain. Pharmacology of potassium channels","volume":"267","author":"Liu","year":"2021","journal-title":"Handb. Exp. Pharmacol."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110658_bib24","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.seizure.2011.01.003","article-title":"Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs","volume":"20","author":"Loscher","year":"2011","journal-title":"Seizure"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110658_bib25","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0920-1211(88)90054-X","article-title":"Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations","volume":"2","author":"Loscher","year":"1988","journal-title":"Epilepsy Res."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110658_bib26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0026-895X(24)12060-3","article-title":"Modulation of KCNQ2\/3 potassium channels by the novel anticonvulsant retigabine","volume":"58","author":"Main","year":"2000","journal-title":"Mol. Pharmacol."},{"issue":"23","key":"10.1016\/j.neuropharm.2025.110658_bib27","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.2174\/0929867324666171012122852","article-title":"Pharmacological targeting of neuronal Kv7.2\/3 channels: a focus on chemotypes and receptor sites","volume":"25","author":"Miceli","year":"2018","journal-title":"Curr. Med. Chem."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110658_bib28","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1212\/NXG.0000000000000096","article-title":"KCNQ2 encephalopathy: features, mutational hot spots, and ezogabine treatment of 11 patients","volume":"2","author":"Millichap","year":"2016","journal-title":"Neurol. Genet."},{"key":"10.1016\/j.neuropharm.2025.110658_bib29","series-title":"2nd International Kv7 Channel Symposium","article-title":"Discovery of potent Kv7 openers by phenotypic screening with in vivo antiseizure activity","author":"M\u00fchlemann","year":"2023"},{"issue":"16","key":"10.1016\/j.neuropharm.2025.110658_bib30","doi-asserted-by":"crossref","first-page":"11340","DOI":"10.1021\/acs.jmedchem.2c00911","article-title":"Beyond retigabine: design, synthesis, and pharmacological characterization of a potent and chemically stable neuronal Kv7 channel activator with anticonvulsant activity","volume":"65","author":"Musella","year":"2022","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110658_bib31","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/ana.24883","article-title":"Genetics and genotype-phenotype correlations in early onset epileptic encephalopathy with burst suppression","volume":"81","author":"Olson","year":"2017","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110658_bib32","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40263-024-01155-3","article-title":"Targeting Kv7 potassium channels for epilepsy","volume":"39","author":"Perucca","year":"2025","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110658_bib33","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0920-1211(95)00101-8","article-title":"D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures","volume":"23","author":"Rostock","year":"1996","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2025.110658_bib34","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.seizure.2019.10.020","article-title":"Risk factors associated with drug resistant focal epilepsy in adults: a case control study","volume":"73","author":"Roy","year":"2019","journal-title":"Seizure"},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2025.110658_bib35","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0304-3940(00)00866-1","article-title":"The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2\/3 subunits","volume":"282","author":"Rundfeldt","year":"2000","journal-title":"Neurosci. Lett."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110658_bib36","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1124\/mol.54.1.220","article-title":"A novel benzodiazepine that activates cardiac slow delayed rectifier K+ currents","volume":"54","author":"Salata","year":"1998","journal-title":"Mol. Pharmacol."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110658_bib37","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/0013-4694(90)90099-6","article-title":"Kindling: basic mechanisms and clinical validity","volume":"76","author":"Sato","year":"1990","journal-title":"Electroencephalogr. Clin. Neurophysiol."},{"issue":"20","key":"10.1016\/j.neuropharm.2025.110658_bib38","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1523\/JNEUROSCI.0128-05.2005","article-title":"Molecular determinants of KCNQ (Kv7) K+ channel sensitivity to the anticonvulsant retigabine","volume":"25","author":"Schenzer","year":"2005","journal-title":"J. Neurosci."},{"issue":"11","key":"10.1016\/j.neuropharm.2025.110658_bib39","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1111\/j.1528-1167.2010.02759.x","article-title":"Assessing the unmet treatment need in partial-onset epilepsy: looking beyond seizure control","volume":"51","author":"Schmitz","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2025.110658_bib40","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.5c00945","article-title":"Mimicking epilepsy in a dish: discovery and in-vivo characterization of Kv7.X channel openers through a phenotypic approach","author":"Siegrist","year":"2025","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110658_bib41","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1152\/physiol.00009.2011","article-title":"Driving with no brakes: molecular pathophysiology of Kv7 potassium channels","volume":"26","author":"Soldovieri","year":"2011","journal-title":"Physiology"},{"issue":"15","key":"10.1016\/j.neuropharm.2025.110658_bib42","doi-asserted-by":"crossref","first-page":"5535","DOI":"10.1523\/JNEUROSCI.21-15-05535.2001","article-title":"Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine","volume":"21","author":"Tatulian","year":"2001","journal-title":"J. Neurosci."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110658_bib43","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/epi.12633","article-title":"A validation of the new definition of drug-resistant epilepsy by the international league against epilepsy","volume":"55","author":"Tellez-Zenteno","year":"2014","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110658_bib44","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0014-2999(96)00073-8","article-title":"D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures","volume":"303","author":"Tober","year":"1996","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110658_bib45","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2174\/15748847113089990053","article-title":"Clinical pharmacokinetics of retigabine\/ezogabine","volume":"8","author":"Tompson","year":"2013","journal-title":"Curr. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.neuropharm.2025.110658_bib46","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1111\/epi.18092","article-title":"Identification of a new retigabine derivative with improved photostability for selective activation of neuronal Kv7 channels and antiseizure activity","volume":"65","author":"Wang","year":"2024","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110658_bib47","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/ana.22644","article-title":"KCNQ2 encephalopathy: emerging phenotype of a neonatal epileptic encephalopathy","volume":"71","author":"Weckhuysen","year":"2012","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110658_bib48","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1124\/mol.58.3.591","article-title":"Retigabine, a novel anti-convulsant, enhances activation of KCNQ2\/Q3 potassium channels","volume":"58","author":"Wickenden","year":"2000","journal-title":"Mol. Pharmacol."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110658_bib49","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1124\/mol.104.010793","article-title":"The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate","volume":"67","author":"Wuttke","year":"2005","journal-title":"Mol. Pharmacol."},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110658_bib50","doi-asserted-by":"crossref","first-page":"9154","DOI":"10.1096\/fj.201802848RR","article-title":"Electrophysiological and pharmacological characterization of a novel and potent neuronal Kv7 channel opener SCR2682 for antiepilepsy","volume":"33","author":"Zhang","year":"2019","journal-title":"FASEB J."},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110658_bib51","doi-asserted-by":"crossref","first-page":"5816","DOI":"10.1021\/acs.jmedchem.0c02252","article-title":"Discovery of HN37 as a potent and chemically stable antiepileptic drug candidate","volume":"64","author":"Zhang","year":"2021","journal-title":"J. Med. Chem."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825003661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825003661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T21:21:35Z","timestamp":1768512095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390825003661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":51,"alternative-id":["S0028390825003661"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110658","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IDOR-1104-0086, a novel Kv7 channel activator with antiseizure effects in rodents","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110658","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110658"}}